Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 826 AL 840

Alzheimer's Disease Has Its Origins in Early Life via a Perturbed Microbiome

Ginsberg SD, Blaser MJ.

J Infect Dis. 2024 Sep 10;230(Supplement_2):S141-S149. doi: 10.1093/infdis/jiae200.

Amyloid-β-targeting immunotherapies for Alzheimer's disease

Jin Y, Du Q, Song M, Kang R, Zhou J, Zhang H, Ding Y.

J Control Release. 2024 Nov;375:346-365. doi: 10.1016/j.jconrel.2024.09.012. Epub 2024 Sep 18.

Therapeutic Targets in Innate Immunity to Tackle Alzheimer's Disease

Serradas ML, Ding Y, Martorell PV, Kulińska I, Castro-Gomez S.

Cells. 2024 Aug 26;13(17):1426. doi: 10.3390/cells13171426.

Alzheimer's Disease Pathology and Assistive Nanotheranostic Approaches for Its Therapeutic Interventions

Dey A, Ghosh S, Rajendran RL, Bhuniya T, Das P, Bhattacharjee B, Das S, Mahajan AA, Samant A, Krishnan A, Ahn BC, Gangadaran P.

Int J Mol Sci. 2024 Sep 7;25(17):9690. doi: 10.3390/ijms25179690.

Latest Perspectives on Alzheimer's Disease Treatment: The Role of Blood-Brain Barrier and Antioxidant-Based Drug Delivery Systems

Daraban BS, Popa AS, Stan MS.

Molecules. 2024 Aug 27;29(17):4056. doi: 10.3390/molecules29174056.

Multifunctional Tasks and an Energy Crisis are Crucial Players in Determining the Vulnerability of the Entorhinal Cortex to Early Damage in Alzheimer's Disease

Sivanesan S, Howell MD, Kaushik V, Jayakumar R, Pari SM, Goyal P.

Curr Alzheimer Res. 2024;21(5):295-311. doi: 10.2174/0115672050324909240823104209.

Clinical Update on an Anti-Alzheimer Drug Candidate CT1812: A Sigma-2 Receptor Antagonist

Kaur G, Dar ZA, Bajpai A, Singh R, Bansal R.

Clin Ther. 2024 Nov;46(11):e21-e28. doi: 10.1016/j.clinthera.2024.08.013. Epub 2024 Sep 16.

Current pharmacophore based approaches for the development of new anti-Alzheimer's agents

Sharma P, Sharma S, Yadav Y, Shukla P, Sagar R.

Bioorg Med Chem. 2024 Nov 1;113:117926. doi: 10.1016/j.bmc.2024.117926. Epub 2024 Sep 13.

Effect of long-term pharmacological treatments on Alzheimer disease: A systematic review and network meta-analysis

Deng X, Li D.

Medicine (Baltimore). 2024 Sep 20;103(38):e39753. doi: 10.1097/MD.0000000000039753.

Post-Hoc Assessment of Cognitive Efficacy in Alzheimer's Disease Using a Latent Growth Mixture Model in AMBAR, a Phase 2B Randomized Controlled Trial

Ayasse ND, Stewart WF, Lipton RB, Gomez-Ulloa D, Runken MC.

Curr Alzheimer Res. 2024;21(5):353-365. doi: 10.2174/0115672050316936240905064215.

Microglia and gut microbiota: A double-edged sword in Alzheimer's disease

Bano N, Khan S, Ahamad S, Kanshana JS, Dar NJ, Khan S, Nazir A, Bhat SA.

Ageing Res Rev. 2024 Nov;101:102515. doi: 10.1016/j.arr.2024.102515. Epub 2024 Sep 24.

Phyto-nanotechnology: A novel beneficial strategy for Alzheimer's disease therapy

Ganguly SC, Sangram S, Paul S, Kundu M.

Neurochem Int. 2024 Nov;180:105868. doi: 10.1016/j.neuint.2024.105868. Epub 2024 Sep 25.

The role and mechanism of dapagliflozin in Alzheimer disease: A review

Chen P, Liang L, Dai Y, Hui S.

Medicine (Baltimore). 2024 Sep 27;103(39):e39687. doi: 10.1097/MD.0000000000039687.

What's in It for Me? Contextualizing the Potential Clinical Impacts of Lecanemab, Donanemab, and Other Anti-β-amyloid Monoclonal Antibodies in Early Alzheimer's Disease

Jin M, Noble JM.

eNeuro. 2024 Sep 27;11(9):ENEURO.0088-24.2024. doi: 10.1523/ENEURO.0088-24.2024. Print 2024 Sep.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias